Dopa-responsive dystonia (Segawa syndrome)
Kamal, N.; Bhat, D.P.; Carrick, E.
Indian Pediatrics 43(7): 635-638
2006
ISSN/ISBN: 0019-6061 PMID: 16891685 Document Number: 600292
A 12 year old boy with gradually worsening global developmental delay was diagnosed and managed as quadriplegic cerebral palsy since child-hood. Subsequent evaluation revealed marked dystonia over spasticity leading to suspicion of Segawa syndrome. Dramatic improvement in clinical condition followed after therapy with low dose L-Dopa.
Document emailed within 1 workday
Related Documents
Kaakkola, S.; Iivanainen, M. 1994: Dopa-responsive dystonia Duodecim; Laaketieteellinen Aikakauskirja 110(13): 1271-1274Rondot, P.; Ziegler, M. 1983: Dystonia--L-dopa responsive or juvenile parkinsonism? Journal of Neural Transmission. Supplementum 19: 273-281
Takahashi, H.; Snow, B.J.; Nygaard, T.G.; Calne, D.B. 1993: Clinical heterogeneity of dopa-responsive dystonia: PET observations Advances in Neurology 60: 586-590
Furukawa, Y. 2006: Dopa-responsive dystonia: clinical, genetic, and biochemical studies Rinsho Shinkeigaku 46(1): 19-34
Ichinose, H.; Suzuki, T.; Inagaki, H.; Ohye, T.; Nagatsu, T. 2001: DOPA-responsive dystonia. from causative gene to molecular mechanism Advances in Neurology 86: 173-176
Maruta, K.; Okamoto, S.; Takegami, T. 1993: A form of dopa-responsive dystonia of late onset with diurnal fluctuations Rinsho Shinkeigaku 33(3): 341-343
Furukawa, Y.; Shimadzu, M.; Hornykiewicz, O.; Kish, S.J. 1998: Molecular and biochemical aspects of hereditary progressive and dopa-responsive dystonia Advances in Neurology 78: 267-282
Segawa, M. 2009: Autosomal dominant GTP cyclohydrolase i (AD GCH 1) deficiency (Segawa disease, dystonia 5; DYT 5) Chang Gung Medical Journal 32(1): 1-11
Ujike, H.; Nakashima, M.; Kuroda, S.; Otsuki, S. 1989: Two siblings of juvenile Parkinson's disease dystonic type (Yokochi type 3) and hereditary progressive dystonia with marked diurnal fluctuation (Segawa) Rinsho Shinkeigaku 29(7): 890-894
Yoshikawa, H.; Matsuo, T.; Sakuragawa, N. 1990: Effect of L-dopa in dystonia which was worsened by exercise and improved by resting; a care report No to Hattatsu 22(3): 290-292
Bergonzi, P.; Chiurulla, C.; Gambi, D.; Mennuni, G.; Pinto, F. 1975: L-dopa plus dopa-decarboxylase inhibitor. Sleep organization in Parkinson's syndrome before and after treatment Acta Neurologica Belgica 75(1): 5-10
Gherpelli, J.L.; Nagae, L.M.; Diament, A. 1995: DOPA-sensitive progressive dystonia of childhood with diurnal fluctuations of symptoms: a case report Arquivos de Neuro-Psiquiatria 53(2): 298-301
Christiani, K.; Möller, W.D. 1973: Drug therapy of Parkinson's syndrome. Clinical long-term study using L-dopa and the drug conbination L-dopa-decarboxylase inhibitor Münchener Medizinische Wochenschrift 115(16): 711-713
Marsden, C.D. 1976: The problem of adult-onset idiopathic torsion dystonia and other isolated dyskinesias in adult life (including blepharospasm, oromandibular dystonia, dystonic writer's cramp, and torticollis, or axial dystonia) Advances in Neurology 14: 259-276
Theau, D.; Missoum, A. 1986: Severe dystonia syndrome successfully treated with bromocriptine and ataxia-telangiectasia syndrome in a single family Archives Francaises de Pediatrie 43(7): 538
Bizzarri, B.Mattia.; Tortolini, S.; Rotelli, L.; Botta, G.; Saladino, R. 2015: Current Advances in L-DOPA and DOPA-Peptidomimetics: Chemistry, Applications and Biological Activity Current Medicinal Chemistry 22(36): 4138-4165
Hansson, C.; Rorsman, H.; Rosengren, E. 1981: Pronounced formation of 5-OH-dopa at enzymatic oxidation of DOPA in the presence of ascorbic acid Acta Dermato-Venereologica 61(2): 147-148
Riley, P.A. 1999: The great DOPA mystery: the source and significance of DOPA in phase i melanogenesis Cellular and Molecular Biology 45(7): 951-960
Guillard, A. 1972: Treatment of Parkinson syndromes with L-Dopa and the association of L-Dopa and a decarboxylase inhibitor Bruxelles Medical 52(10): 673-680
Blair, M.L.; Reid, I.A.; Ganong, W.F. 1977: Effect of L-dopa on plasma renin activity with and without inhibition of extracerebral dopa decarboxylase in dogs Journal of Pharmacology and Experimental Therapeutics 202(1): 209-215